Treatment of Malignant Tumors With NK Cell
NCT05143125
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Malignancy
Interventions
BIOLOGICAL:
Decitabine combined with NK cell infusion
Sponsor
Shenzhen University General Hospital